Research progress on the risk of secondary primary malignancy induced by radioactive iodine therapy for postoperative differentiated thyroid cancer
10.3760/cma.j.cn321828-20230619-00175
- VernacularTitle:分化型甲状腺癌术后放射性碘治疗诱发第二原发恶性肿瘤风险的研究进展
- Author:
Yuxin WANG
1
;
Nan JIANG
;
Qiuyu LIN
;
Shuangyan ZHAO
;
Jiawen WANG
;
Chenghe LIN
Author Information
1. 吉林大学第一医院核医学科，长春 130061
- Keywords:
Thyroid neoplasms;
Radiotherapy;
Iodine radioisotopes;
Neoplasms, second primary;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2024;44(8):500-504
- CountryChina
- Language:Chinese
-
Abstract:
With good prognosis of differentiated thyroid cancer (DTC), the 10-year survival rate of DTC patients is more than 90%. As a kind of radiation exposure, radioactive iodine (RAI) treatment has the potential to induce malignancies. Based on this view, whether RAI treatment will increase the risk of secondary primary malignancy (SPM) still has a lot of controversy. This review summarizes current situation of related researches, and also summarizes the limitations of the current researches and the problems to be solved in the future research. In this review, it is believed that RAI treatment does not increase the overall risk of SPM in postoperative-DTC patients.
